Across TCGA pan-cancer cohorts, HIBCH mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated HIBCH data layer compared with 22 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher HIBCH mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated HIBCH expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

PDAC, LSCC, and CCRCC are the cancer types where HIBCH mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	III,IV	0.708	0.212	.001	36	view →
LSCC	OS	Median	All	1.000	0.937	.012	5	view →
CCRCC	DFS	Quartile	All	1.000	0.553	.018	5	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: HIBCH tumor-vs-normal RNA expression · all HIBCH data types